A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

EK Bancroft; EC Page; MN Brook; S Thomas; N Taylor; J Pope; J McHugh; AB Jones; Q Karlsson; S Merson; KR Ong; J Hoffman; C Huber; L Maehle; EM Grindedal; A Stormorken; DG Evans; J Rothwell; F Lalloo; AF Brady; M Bartlett; K Snape; H Hanson; P James; J McKinley; L Mascarenhas; S Syngal; C Ukaegbu; L Side; T Thomas; J Barwell; MR Teixeira; L Izatt; M Suri; FA Macrae; N Poplawski; R Chen-Shtoyerman; M Ahmed; H Musgrave; N Nicolai; L Greenhalgh; C Brewer; N Pachter; AD Spigelman; A Azzabi; BT Helfand; D Halliday; S Buys; T Ramon y Cajal; A Donaldson; KA Cooney; M Harris; J McGrath; R Davidson; A Taylor; P Cooke; K Myhill; M Hogben; NK Aaronson; A Ardern-Jones; CH Bangma; E Castro; D Dearnaley; A Dias; T Dudderidge; DM Eccles; K Green; J Eyfjord; A Falconer; CS Foster; H Gronberg; FC Hamdy; O Johannsson; V Khoo; H Lilja; GJ Lindeman; J Lubinski; K Axcrona; C Mikropoulos; AV Mitra; C Moynihan; H Ni Raghallaigh; G Rennert; R Collier; L Adams; J Adlard; R Alfonso; S Ali; A Andrew; L Araújo; N Azam; D Ball; Q Barker; A Basevitch; B Benton; C Berlin; N Bermingham; L Biller; A Bloss; M Bradford

Journal article

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

EK Bancroft, EC Page, MN Brook, S Thomas, N Taylor, J Pope, J McHugh, AB Jones, Q Karlsson, S Merson, KR Ong, J Hoffman, C Huber, L Maehle, EM Grindedal, A Stormorken, DG Evans, J Rothwell, F Lalloo, AF Brady Show all

Lancet Oncology | Published : 2021

DOI: 10.1016/S1470-2045(21)00522-2

Download PDF

Abstract

Background: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic..

View full abstract

University of Melbourne Researchers

Paul James Author

Finlay Macrae Author

Geoffrey Lindeman Author

Declan Murphy Author

Related Projects (1)

The IMPACT Study

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

The IMPACT study is funded by Cancer Research UK (grant references C5047/A21332, C5047/ A13232, and C5047/A17528) and The Ronald and Rita McAulay Foundation and the National Institute for Health Research (NIHR) support to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. JO is supported by Cancer Research UK Programme Grant (reference C8161/A16892). We thank Mr and Mrs Jack Baker for supporting the study in NorthShore University HealthSystem, Evanston, IL, USA. We acknowledge funding from the NIHR to the Biomedical Research Centre at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, at Manchester University Foundation Trust (IS-BRC-1215-20007), the Oxford Biomedical Research Centre Program, and the Cambridge Clinical Research Centre, NIHR Cambridge Biomedical Research Centre. DGE is supported by the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007). We acknowledge that, in Australia, this project was co-funded by Cancer Council Tasmania and Cancer Australia (grant number 1006349 [2011-13]), Prostate Cancer Foundation of Australia (grant number PCFA PRO4 [2008]), Cancer Councils of Victoria and South Australia (grant number 400048 [2006-08]), the Victorian Cancer Agency Clinical Trial Capacity CTCB08_14, Cancer Australia and Prostate Cancer Foundation of Australia (2014-16; grant number 1059423), and Translational grants EOI09_50. We acknowledge the support of the Asociacion Espanola Contra el Cancer (AECC), the Instituto de Salud Carlos III (organismo adscrito al Ministerio de Economia y Competitividad), "Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa" (PI10/01422, PI13/00285, PIE13/00022, PI16/00563, JR18/00011 and CIBERONC), and the Institut Catala de la Salut and Autonomous Government of Catalonia (2009SGR290, 2014SGR338 and PERIS Project MedPerCan). We acknowledge funding support from Fundacao para a Ciencia e a Tecnologia to the IPO Porto study (project grant PTDC/DTP-PIC/1308/2014 to MRT and fellowship grant SFRH/BD/116557/2016). We acknowledge funding support to HL from the National Institutes of Health National Cancer Institute with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748), a SPORE grant in Prostate Cancer (P50 CA092629), Swedish Cancer Society (Cancerfonden 20 1354 PjF), and General Hospital in Malmo Foundation for Combating Cancer. This research is sponsored and coordinated by The Institute of Cancer Research (London, UK) and reviewed by the Committee for Clinical Research at the Royal Marsden NHS Foundation Trust and West Midlands - Edgbaston REC. The funding bodies supported recruitment but did not have any input into study design, the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. We are indebted to all the men who took part in this study. We are grateful to the past and present members of the Data and Safety Monitoring Committee (appendix p 2). We acknowledge the contribution of past members of the IMPACT Steering Committee.